NMRA
Neumora Therapeutics, Inc.
NASDAQ: NMRA · HEALTHCARE · BIOTECHNOLOGY
$1.00
-3.90% today
Updated 2026-09-14
Market cap
$253.66M
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-1.20
Dividend yield
—
52W range
$1 – $4
Volume
0.8M
WallStSmart proprietary scores
20
out of 100
Grade: F
Strong Sell
Investment rating
4.3
Growth
C6.0
Quality
B3.0
Profitability
D5.0
Valuation
C+1/9
Piotroski F-Score
Weak
-11.0
Altman Z-Score
Distress
—
Industry rank
—
View all highly rated stocks (75+) →251 stocks currently score above 75
Price targets
Analyst target
$6.14
+514.37%
12-Month target
—
—
Intrinsic (DCF)
—
Margin of safety
—
2 Strong Buy5 Buy1 Hold0 Sell1 Strong Sell
Price chart
Stock snapshot
Strengths
+ Debt/equity 0.01x — low leverage
Risks
- Piotroski 1/9 — weak financial health
- Altman Z -11.00 — distress zone
- Thin margins at 0.00%
- Negative free cash flow $-39.53M
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net income | $-130.90M | $-235.93M | $-243.79M | $-236.93M | $-43.08M |
| EPS | — | — | — | — | $-1.20 |
| Free cash flow | $-115.41M | $-163.40M | $-182.94M | $-206.44M | $-39.53M |
| Profit margin | — | — | — | — | — |
Peer comparison
Smart narrative
Neumora Therapeutics, Inc. trades at $1.00. Our Smart Value Score of 20/100 indicates the stock is weak. The company scores 1/9 on the Piotroski F-Score. With an Altman Z-Score of -11.00, it sits in the distress.
Frequently asked questions
What is Neumora Therapeutics, Inc.'s stock price?
Neumora Therapeutics, Inc. (NMRA) trades at $1.00.
Is Neumora Therapeutics, Inc. overvalued?
Neumora Therapeutics, Inc. carries a Smart Value Score of 20/100 (Grade F), which we rate Strong Sell. That score blends growth, quality, and valuation into one read.
What is the price target of Neumora Therapeutics, Inc. (NMRA)?
The 12-month analyst consensus target is $6.14, about 514.4% above the current $1.00. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
Altman Z-Score?
Neumora Therapeutics, Inc.'s Altman Z-Score is -11.00, which places it in the distress. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio—
ROE-314.65%
Beta2.78
50D MA$1.59
200D MA$2.08
Shares out0.19B
Float0.12B
Short ratio—
Avg volume0.8M
Performance
1 week-4.51%
1 month+6.88%
3 months+9.91%
YTD+30.17%
1 year—
3 years—
5 years—